Search the Newsreel

Bioatla Inc (BCAB) Institutional Confidence

Bioatla Inc (BCAB) has an institutional shareholding score of 3.00, ranking 192 out of 386 in its industry. The institutional shareholding proportion is 19.70%, a quarter-over-quarter decrease of 68.85%. James Simons is the largest institutional shareholder with 0.62% of outstanding shares.

BCAB|Bioatla Inc|Price:3.481|Chg%:+0.091

Bioatla Inc. (BCAB) is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumor cancer, with a valuation considered fairly valued. Despite an average stock market performance over the last month, the company shows strong fundamentals and high growth potential, although its …

bioAffinity Technologies, Inc. (BIAF) Stock Price, News, Quote & History

This article provides detailed financial information and an overview of bioAffinity Technologies, Inc. (BIAF). It covers the company's stock performance, key financial metrics, news, and its work in developing non-invasive diagnostic tests for early-stage lung cancer and other lung diseases. The company utilizes flow …

bioAffinity Technologies partners with Pictor to develop high-throughput asthma and COPD diagnostics

bioAffinity Technologies announced a collaboration with Pictor to develop high-throughput diagnostics for asthma and COPD, integrating bioAffinity's flow cytometry sputum platform with Pictor's proteomic analysis. This partnership aims to enhance lab throughput, reduce costs, and offer scalable diagnostic testing. bioAffinity will retain IP rights …

BioAge Labs (BIOA) price target increased by 44.67% to 44.27

The article reports that the price target for BioAge Labs (BIOA) has been increased by 44.67%, raising it to 44.27. No further details regarding the reasons for this increase or who issued the target are provided.

Price to earnings forward of BioAge Labs, Inc. – FWB:Y7G

This article displays the "Price to earnings forward" metric for BioAge Labs, Inc. (FWB:Y7G) on the TradingView platform. The content is primarily a data placeholder, indicating the period, value, and change for this financial metric, but the specific numerical data fields are left blank. …

Certain Common Stock of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026.

Certain Common Stock of bioAffinity Technologies, Inc. are subject to a lock-up agreement that concludes on July 19, 2026. This agreement restricts officers and directors from selling or otherwise disposing of their common stock for 31 days, from June 18, 2026, to July 19, …

BioAge Labs Q1 2026 Earnings: Loss Narrower Than Expected, Stock Rises - Revenue Miss Report

BioAge Labs, Inc. (NASDAQ:BIOA) Given Average Recommendation of "Moderate Buy" by Analysts

BioAtla, Inc. 8-K SEC Filing: Company Profile, Key Data, and Stock Information for July 2026

BioAtla, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected two Class III directors, ratified Ernst & Young LLP as their independent auditor, and approved executive compensation on an advisory basis. The meeting, which had 55% representation of outstanding shares, addressed routine …

CyPath Lung sales top prior quarter as bioAffinity sees 200% growth

BioAffinity Technologies Projects Strong Growth Amid Market Fluctuations

BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung

BIAF Stock Gains As CyPath Sales Surge 146% In Q1

bioAffinity Technologies 10-K: Revenue $6.16M, EPS $(8.66)

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

bioAffinity Technologies (BIAF) Earnings Date and Reports 2026 $BIAF

bioAffinity Technologies, Inc. (BIAF)